The use of CO2 removal devices in patients awaiting lung transplantation: an initial experience. by Ricci, Davide et al.
14 December 2021
AperTO - Archivio Istituzionale Open Access dell'Università di Torino
Original Citation:





(Article begins on next page)
Anyone can freely access the full text of works made available as "Open Access". Works made available under a
Creative Commons license can be used according to the terms and conditions of said license. Use of all other works
requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.
Availability:
This is the author's manuscript
This version is available http://hdl.handle.net/2318/73709 since
 
 
This Accepted Author Manuscript (AAM) is copyrighted and published by Elsevier. It is posted here 
by agreement between Elsevier and the University of Turin. Changes resulting from the publishing 
process - such as editing, corrections, structural formatting, and other quality control mechanisms - 
may not be reflected in this version of the text. The definitive version of the text was subsequently 
published in TRANSPLANTATION PROCEEDINGS (ISSN:0041-1345), pp. 1255- 1258. Vol. 
42, 2010, DOI  10.1016/j.transproceed.2010.03.117 
 
You may download, copy and otherwise use the AAM for non-commercial purposes provided that 
your license is limited by the following restrictions: 
 
(1) You may use this AAM for non-commercial purposes only under the terms of the CC-BY-NC-ND 
license.  
(2) The integrity of the work and identification of the author, copyright owner, and publisher must be 
preserved in any copy.  














Pre-transplant extracorporeal decapneization devices: a single center initial experience   
 
 
Davide Ricci, MD¹ 
Massimo Boffini MD¹ 
Marco Ribezzo MD¹ 
Riccardo Bonato MD¹ 
Carlo Del Sorbo, MD² 
Chiara Comoglio, MD¹ 
Vito Marco Ranieri, MD² 
Mauro Rinaldi, MD¹ 
 
 
¹ Division of Cardiac Surgery, San Giovanni Battista Hospital "Molinette", University of Torino, 10126 
Torino Italy 










Address for correspondence: 
Davide Ricci, MD 
Division of Cardiac Surgery 
San Giovanni Battista Hospital "Molinette", University of Torino  
10126 Torino, Italy 
Telephone:  +390116336131 







 Lung transplantation is the treatment of choice for patients with end-stage lung failure. The most 
important limitations are represented by the shortage of donors and the too long period on waiting list. 
New techniques such as extracorporeal membrane ventilator devices with or without pump support have 
been developed as bridge to transplant for those patients with severe unresponsive respiratory 
insufficiency. 
Methods 
 Between November 2005 and September 2009, 12 patients (7 male and 5 female; mean age 43.3 
± 15.5 years) underwent  decapneization with extracorporeal devices. In 6 cases a NovaLung system has 
been used while in the remaining 6 patients a Decap device has been applied. The causes of respiratory 
failure that led to the implantation of such devices were: cystic fibrosis (6 pts), pulmonary emphysema (4 
pts), obliterant bronchiolitis (1 pts) and one case of chronic rejection in a previous double lung 
transplantation 
Results 
 Mean time on extracorporeal decapneization has been 13.5 ± 14.2 days. 8/12 patients (67%) died 
on device. In 3 cases patients were bridged to lung transplantation, while 1 patient recovered from the 
acute phase and was weaned from the device after 11 days. Mean PaCO2 on extracorporeal gas 
exchange has been significantly lower for both the devices at 24, 48 and 72 hours after assistance 
implantation (p<0.05). No statistical difference has been observed for both the systems used. 
Conclusions 
 In our initial experience the decapneization devices used have been simple and efficient methods 
to support  patients with mild hypoxia and severe hypercapnia  refractory to mechanical ventilation. This 
could represent a valid bridge to lung transplant  in such patients. The limited number of available donors 








 The number of patients listed for lung transplantation (Ltx) is continuously rising. Even if lung 
transplant procedures are annually increasing the number of patients waiting for LTx still overcomes the 
number of available grafts 1. The need for alternative solutions as bridge to transplants or to recovery, 
especially in the acute pulmonary failure, is becoming more and more important. Critically ill patients 
with severe pulmonary distress, characterized by respiratory insufficiency with severe hypoxemia and 
hypercapnia, often require invasive ventilatory support. Mechanical ventilation forces lungs to work 
under unphysiologic positive pressure. This condition, even with protective respiratory settings (low tidal 
volumes), brings to variuous degrees of barotrauma, volutrauma and biotrauma 2. In addition it increases 
the risk of lung injury, infection, atelectasis, muscle fatigue, remote organ failure 3, 4 and it is recognized 
to be a significant risk factor for mortality after LTx 5. Most of the patients, despite maximal mechanical 
ventilatory support, develop refractory hypercapnia and acidosis that require additional extracorporeal 
gas exchange. 
 Alternatively to the extracorporeal membrane oxigenation (ECMO), widely used until now, new 
devices such as the interventional lung assist NovaLung (iLA; NovaLung GmbH, Hecnigen, Germany) and 
the decapneization system Decap®  6, 7 have been applied. ILA is a low resistance lung assist device driven 
by the cardiac output that does not require extracorporeal pump assistance, it provides veno-arterious 
passive carbon dioxide removal by a diffusion membrane. On the contrary the Decap® system allows 
veno-venous extra-corporeal CO2 removal with a mini-invasive pump driven easy-to-use technique.   
 In this manuscript we report our experience with both the devices as bridge to transplant in 
patients on waiting list for LTx, with severe and unresponsive pulmonary failure. 
 
Materials and Methods 
 At our institution from November 2005 to September 2009, 12 patients (7 males, 5 females, 
mean age 43.3 ± 15.5 years), on waiting list for lung transplantation, have been treated with 
extracorporeal devices for CO2 removal because of a severe ventilation-refractory hypercapnia and 
respiratory acidosis. In 6 patients a Decap® system was used, the remaining 6 patients underwent iLA 
implantation. The decision on what device to use was made on the base of the hemodynamic capability 
of the patient to sustain extracorporeal gas exchange with or without the interposition of a centrifugal 
pump. Patients with an adequate mean arterial pressure to drive blood through the system have been 
treated with pumpless apparatus (iLA), those, supposed not to be able to sustain an extracorporeal gas 
exchange, have been supported with a Decap® device. No statistical difference was found in terms of 
patient characteristics between the two groups (data not shown). 
 Novalung has been implanted with the standard technique 8. For the Decap® system, cannulation 
consisted in the insertion of a percutaneous single access with a double lumen catheter connected to a 
veno-venous circuit drived with a low flow pump (< 40 ml/min). A bolus of 5000 UI of heparin was 
administered intravenously followed by titrated administration to maintain the active clotting time value 
between 150 and 200. Administration of fluids, as well as vasopression or inotropic agents was targeted to 
maintain a mean arterial pressure (MAP) of 65 mm Hg 6, 7. Perfusion of the lower extremities has been 
checked every day with Doppler examination. 
 In all patients arterial blood gas samples were taken at the moment of the implantation, 24, 48, 
72 hours and 7 days after implantation.  
 
Statistical Analysis 
 Data are presented as mean±SD, median (range) or frequencies (percent). Patients's 
characteristics of the femoral and direct aortic cannulation groups were compared with Student's t-test. 
Statistical significance was accepted for P values <0.05. 
 
Results 
 All patients except one were on mechanical ventilatory support before the implant of the 
devices. The indication for decapneization device implantation was severe hypercapnia and acidosis 
refractory to positive high pressure mechanical ventilation. The only one not on ventilator was a lung 
transplanted patient treated with iLA because of a respiratory failure due to worsening of chronic 
rejection. This patient has been on iLA assistance, not intubated until lung re-transplantation. The 
diseases were: cystic fibrosis (6 pts), pulmonary emphysema (5 pts) and one case of chronic rejection in a 
previous double lung transplantation (table 1). The global mean duration on decapneization support was 
13.5 ± 14.2 days (median 7.5, range 4 – 48 days), no statistical difference has been observed between iLA 
and Decap®. Pre and post implant changes in blood gases are shown in figure 1. There was s significant 
reduction in PaCO2 levels at 24, 48 and 72 hours post implant for both the extracorporeal systems used. 
No statistical difference was found at each time point in terms of PaO2 levels either pre versus post 
device implantation or iLA versus Decap® system. In only one case, because of thrombosis of the iLA a 
membrane replacement was required while cannulas were left in place. Only one patient was firstly 
weaned from ventilator and later from the Deca®p for a total period on device of 11 days. This patient is 
still on waiting list for double lung transplantation. Three patients (25%) has been successfully 
transplanted while the remaining eight died under decapneization treatment. Causes of death are 
summarized in table 2.  
 
Discussion 
 The aim of percutaneous extracorporeal lung assistance devices insertion is to allow lung 
protective ventilation improving gas exchange and reducing, at the same time, high pressure-high volume 
mechanical ventilation lung damage. In this way, native lung function is supported and the diseased lung 
may better and quickly recover from the acute respiratory failure as artificial ventilation can be 
downregraded. Our results confirm the decapneization efficacy of iLA and Decap® at 24, 48 and 72 hours 
post implantation of such devices in patients on waiting list for lung transplantation with acute 
respiratory failure refractory to mechanical high pressure ventilator support. No difference of PaCO2 post 
versus pre implantation has been observed, for both the devices, after seven days of extracorporeal CO2 
removal. This data has to be critically analyzed taking into account that 50% of the patients were affected 
by cystic fibrosis and in 6 over 12 patients the duration of extracorporeal support has been lower than 7 
days (3 underwent lung transplantation and 3 died on device because of severe pseudomonas 
pneumonia). No improvements in blood oxygenation has been found after the devices implantation. This 
evidence correlates with the purpose and design of both the systems used.  
 In our experience, the decision on what device to be used was made on the base of the 
emodinamic conditions. In patients with an adequate mean arterial pressure we used pumpless 
apparatus (iLA), while in the others we preferred a Decap® device. Thus, hemodynamic judgment before 
insertion of such devices is mandatory. For that purpose an echocardiographic evaluation to assess 
myocardial function and to estimate cardiac index has to be performed. In alternative, when possible, a 
Swan-Ganz catheterization may be beneficial in order to define which assistance to use.  
 We found no differences between the two extracorporeal assistances, this finding permitted us 
to extend the indication of extracorporeal decapneization also to those patients that previously would 
have been treated with ECMO and/or with high-pressure mechanical ventilation, two conditions that are 
widely recognized to negatively affect lung transplantation outcomes. Moreover ECMO brings to various 
side-effects such as infections, renal insufficiency, haemolysis and bleeding complications 9. On the other 
hand invasive high pressure mechanical ventilation is responsible for different forms of lung damage like 
barotaruma , volutrauma, biochemical trauma and athelectrauma (ventilator associated lung injuries-
VALI) 2, 10, 11. In severe cases mechanical ventilation under high volume and positive pressure is an 
additional option it is well known to be a risk factor for pot-LTx mortality5, 10, 11 and should be avoided 
under such circumstances if possible.  
 The above mentioned decapneization systems are clearly efficient in case of severe hypercapnia 
but with mild to moderate hypoxia. Veno-arterious ECMO remains the only solution for severely hypoxic 
patients.  
 In conclusion the extracorporeal assistance devices used in our center are clearly efficient and 
safe methods to support patients with deteriorating gas exchange avoiding any further ventilation-
induced lung injury. Elimination of carbon dioxide is more effective than oxygenation. Thus, indications 
for these systems remain severe hypercapnia and respiratory acidosis with moderate hypoxia especially 
as bridge to transplant and bridge to recovery in patients either in waiting list or with primary graft 
dysfunction. Pumpless assistances and low flow pump driven devices ensured similar results permitting 
us to extend the indications also to those patients previously only eligible for ECMO. The limited number 
of lung transplantations performed due to a restriction of available lung donors still remains the major 
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Table 1. Patients' characteristics  (N= 12)
Age 43.3 ± 15.6 years
Male 7 pts (58.3%) 
Etiology
Cystic Fibrosis 6 pts (50%)
Pulmonary Emphysema 5 pts (41.7%)
Chronic Rejection in previous LTx 1 pt (8.3%)
Treatment 
iLA 6 pts (50%)
Decap® 6 pts (50%)
 
Table 2. Patients’ outcomes (N=12)
Mean time of decapneization
iLA
Decap®
13.5 ± 14.2 days
20.5 ± 17.9 days


























LTx 3 pts (25%)

















Figure 1. Changes in blood gases 
0h 24h 48h 72h 7d
PaCO2 86.00 69.21 68.67 75.92 79.86
PaO2 95.33 102.75 115.67 106.08 107.00
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